Quantcast

Latest Renal cell carcinoma Stories

2010-11-23 10:45:00

BURLINGTON, Mass., Nov. 23, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that projected improvements in recurrence-free survival and a discontinuation of the historically observed increases in the incidence rate of renal cell carcinoma (RCC) will limit growth of new drug-treatment opportunities for advanced disease in RCC. According to analysis of Pharmacor Patient Flow Model Renal Cell...

2010-11-19 06:55:00

NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when compared to sorafenib, in the study population. Consistent with previous analyses, axitinib demonstrated a generally...

2010-11-19 00:00:46

Galil Medical's TRACE Renal Registry tracks the use and effectiveness of kidney cryotherapy. Arden Hills, MN (PRWEB) November 18, 2010 Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, announced today that Medical University of South Carolina enrolled their first TRACE Registry patient. The TRACE (Tracking Renal Tumors After Cryoablation Evaluation) Registry will allow physicians and the company to follow and evaluate the use and effectiveness of...

2010-11-03 16:08:00

EAST HANOVER, N.J., Nov. 3, 2010 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor® (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS)(1,2). This study, which was previously presented at the 46th American Society of Clinical Oncology annual meeting, is the first prospective clinical...

2010-11-02 07:00:00

DURHAM, N.C., Nov. 2, 2010 /PRNewswire/ -- Argos Therapeutics today announced that Fred Miesowicz, the company's chief operating officer and vice president of manufacturing, will present on the implementation, cost effectiveness and benefits of automation for Argos' Arcelis(TM) immunotherapy at The Cell Therapy Industry Summit-2010 in Carlsbad, Calif. at 2 p.m. PDT on Thursday, Nov. 4. The conference will take place at the Sheraton Carlsbad Resort & Spa. Argos recently announced...

2010-11-01 09:25:00

Cancer drug now approved to treat rare genetic disorder SILVER SPRING, Md., Nov. 1, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo:...

2010-10-26 07:00:00

DURHAM, N.C., Oct. 26 /PRNewswire/ -- Argos Therapeutics today announced that it will host a Webinar with leading researchers in renal cell carcinoma (RCC) to discuss novel therapies, recently approved or in development, as well as the promise of personalized immunotherapy in the treatment of RCC. In light of the first FDA approval of an autologous cellular immunotherapy, Dendreon Corporation's PROVENGE(®), three researchers will provide different perspectives on...

2010-10-25 07:00:00

BURLINGTON, Mass., Oct. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of renal cell carcinoma (RCC), the majority of surveyed European oncologists who favor Pfizer's Sutent indicate that they would switch to an emerging therapy only if it extended progression-free survival (PFS) by at least an additional two to three months, assuming the agent's safety and tolerability...

2010-10-21 00:00:41

Galil Medical's TRACE Renal Registry tracks the use and effectiveness of kidney cryotherapy. Arden Hills, MN (PRWEB) October 20, 2010 Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, announced today that Columbia University Medical Center enrolled their first TRACE Registry patient. The TRACE (Tracking Renal Tumors After Cryoablation Evaluation) Registry will allow physicians and the company to follow and evaluate the use and effectiveness of cryotherapy...

2010-10-11 12:14:00

SAN DIEGO, Oct. 11 /PRNewswire/ -- More than 120 cancer survivors and caregivers, cancer-treating physicians, and patient advocates gathered in San Diego to share their Proleukin® (aldesleukin for injection) treatment experiences. The theme of the meeting, Celebrating Our (Un)Common Journey Patient Summit, is believed to be the largest-ever gathering of metastatic renal cell carcinoma (kidney cancer) and metastatic melanoma (skin cancer) survivors. The Summit, which...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related